Numerical optimisation of thermoset composites manufacturing processes: A review

The impetus for higher performance, robustness and efficiency in the aerospace, automotive and energy industries has been reflected in more stringent requirements which the composite manufacturing industry needs to comply with. The process design challenges associated with this are significant and can be only partially met by integration of simulation in the design loop. The implementation of numerical optimisation tools is therefore necessary. The development of methodologies linking predictive simulation tools with numerical optimisation techniques is pivotal to identify and therefore develop optimal design conditions that allow full exploitation of the efficiency opportunities in composite manufacturing. Numerical and experimental results concerning the optimisation techniques and methodologies implemented in literature to address the optimisation of thermoset composite manufacturing processes are presented and analysed in this study

Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi

OBJECTIVE: This is a randomized clinical trial comparing estroprogestin (E/P) pill given for 12 months vs. gonadotrophin releasing hormone agonist (GNRHa) given for 4 months followed by E/P pill treatment for 8 months in the relief of endometriosis-related pelvic pain. METHODS: Eligible for the study were women with laparoscopically confirmed endometriosis and pelvic pain lasting 3-12 months after diagnosis. Eligible women were randomly assigned to treatment with E/P pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months (47 patients) vs. tryptorelin 3.75 mg slow release every 28 days for 4 months followed by E/P pill for 8 months (55 patients). RESULTS: At baseline, dysmenorrhea was reported in 46 women allocated to E/P pill only (97.9%), and in all the 55 women allocated to GNRHa+E/P pill. The corresponding value at the 12 months follow-up visit was 14 subjects (35.9%) and 16 subjects (34.8%). The baseline median values of the multidimensional and analog scale were for dysmenorrhea 4 and 6 in the EP only and 3 and 6 in the GNRHa+E/P group. The corresponding value at the 12 months follow-up visit were 2 and 6 and 0 and 5. Non-menstrual pain was reported, respectively, at baseline and 12 month visit by 46 (97.9%) and 15 (38.5%) subjects in the E/P pill group and 49 (89.1%) and 17 (37.0%) of the GNRHa+E/P pill one. The baseline median values of the multidimensional and analog scale were for non-menstrual pain 3 and 5 in the E/P only and 2 and 6 in the GNRHa+E/P group. The corresponding values at the 12 month follow-up visit were 0 and 4 and 0 and 4. These differences between the two groups were not statistically significant

Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a rnadomized trial. Gruppo Italiano per lo studio dell'endometriosi

Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi

Ablation of lesions or no treatment in minimalmild endometriosis in infertile women: a randomized trial

Abstract In order to analyse the efficacy of resection/ablation of minimal/mild endometriotic lesions for improving fertility, we conducted a randomized clinical trial. Eligible patients were women aged 64 36 years who were trying to conceive and had a laparoscopically confirmed diagnosis of minimal/mild endometriosis (stage I or II of the revised American Fertility Society classification) and otherwise unexplained infertility for 65 2 years. Eligible women were randomly assigned to resection or ablation of visible endometriosis (54 patients) or diagnostic laparoscopy only (47 patients). After laparoscopy women tried to conceive spontaneously for 1 year (follow-up period). A total of five women withdrew from the study: three for personal reasons, and two were lost to follow-up. Considering 51 women in the resection/ablation and 45 in the no-treatment group who ended the follow-up period, 12 (24%) in the resection/ablation group and 13 (29%) in the no treatment group conceived; the difference was not significant. Two spontaneous abortions were observed in the resection/ablation group and three in the no-treatment one. Thus the 1 year birth rate was 10 out of 51 women (19.6%) in the resection/ablation group and 10 out of 45 women (22.2%) in the no-treatment group. In conclusion, the results of this study do not support the hypothesis that ablation of endometriotic lesions markedly improves fertility rates

Risk factors for pelvic endometriosis in women with pelvic pain or infertility

Objective: The objective of the study was to analyse the relationship between selected characteristics and risk of pelvic endometriosis. Study design: Eligible for the study were 817 women with primary or secondary infertility or pelvic pain requiring laparoscopy. Of these, 393 were included for infertility and 424 for pelvic pain. Results: A total of 345 (42.2%) had a diagnosis of endometriosis and 472 did not have the disease. Multiparous women had endomertriosos less frequently than nulliparous, the estimated odds ratios (OR) were respectively 0.9 (95% confidence interval, CI, 0.5-1.6) and 0.4 (95% CI 0.2-0.7) in women reporting one and two or more births. In comparison with women reporting no spontaneous abortion, the estimated OR was 0.3 (95% CI 0.2-0.5) in those who reported greater than or equal to 1 miscarriage. In comparison with women reporting menstrual cycles lasting greater than or equal to 25 days subjects with totally irregular menstrual cycles had a reduced risk of endometriosis (OR 0.6, 95% CI 0.3-0.9). No significant association emerged between smoking, age at menarche and risk of endometriosis. Conclusions: this study confirms, with a different methodological approach to previously published studies, that multiparity, a history of abortion and lifelong irregular menstrual pattern decrease the risk of endometriosis in women with pelvic pain and infertility. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved

Previous abortions and risk of pelvic endometriosis.

To re-analyse the association between spontaneous and induced abortion and the risk of pelvic endometriosis, a total of 817 women with primary or secondary infertility or pelvic pain requiring laparoscopy were studied. Using women who had reported no spontaneous abortions as comparison group, the estimated odd ratios of endometriosis was 0.3 [95% IC 0.2-0.7] in those who reported at least one miscarriage. Likewise, using as comparison group women reporting no induced abortions abortion, the estimated odd ratios of endometriosis was 0.3 [95% IC 0.2-0.7] in women who had undergone one or more induced abortions. The observation of a reduced risk of endometriosis in women reporting a history of induced abortion can probably be explained by the higher fertility of women reporting induced abortions. This suggests that infertility, more than pregnancy itself, may be associated with a risk of the disease. In addition, we found no relationship between a history of miscarriage and the risk of endometriosis, suggesting that endometriosisis not associated with spontaneous abortion

Oral contraceptive use and risk of endometriosis. Italian Endometriosis Study Group.

Objective. To analyse the association between use of oral contraception and risk of pelvic endometriosis. Design. We compared use of oral contraception in women with and without endometriosis. Participants. Eligible for the study were women with primary or secondary infertility (n = 393) or chronic pelvic pain (n = 424), requiring laparoscopy, consecutively observed between September 1995 and January 1996 in 15 obstetrics and gynaecology departments in Italy. Results. Out of the 817 women included in the study, 345 had a diagnosis of endometriosis; 164 (47.5%) women with endometriosis and 139 (29.4%) without the disease reported ever using oral contraception. In comparison with never users the estimated odds ratios (OR) of endometriosis were 1.8 (95% CI 1.0-3.3) in current users and 1.6 (95% CI 1.1-2.4) in ex-users. No clear relation emerged between duration of oral contraceptive use and risk of endometriosis. In comparison with never users, the OR was 1.8 (95% CI 1.1-3.0) for women reporting their last use of oral contraception < 5 years before interview and 1.5 (95% CI 0.9-2.5) for those reporting their last use 65 5 years before interview. Conclusions. The study suggests that oral contraception is associated with an increased risk of endometriosis but this finding is based on a selected population and cannot generalised to all women with endometriosis

Oral contraceptive use and risk of endometriosis

Objective To analyse the association between use of oral contraception and risk of pelvic endometriosis. Design We compared use of oral contraception in women with and without endometriosis. Participants Eligible for the study were women with primary or secondary infertility (n = 393) or chronic pelvic pain (n = 424), requiring laparoscopy, consecutively observed between September 1995 and January 1996 in 15 obstetrics and gynaecology departments in Italy. Results Out of the 817 women included in the study, 345 had a diagnosis of endometriosis; 164 (47.5%) women with endometriosis and 139 (29.4%) without the disease reported ever using oral contraception. In comparison with never users the estimated odds ratios (OR) of endometriosis were 1.8 (95% CI 1.0-3.3) in current users and 1.6 (95% CI 1.1-2.4) in ex-users. No clear relation emerged between duration of oral contraceptive use and risk of endometriosis. In comparison with never users, the OR was 1.8 (95% CI 1.1-3.0) for women reporting their last use of oral contraception < 5 years before interview and 15 (95% CI 0.9-2.5) for those reporting their last use greater than or equal to 5 years before interview. Conclusions The study suggests that oral contraception is associated with an increased risk of endometriosis but this finding is based on a selected population and cannot generalised to all women with endometriosis